NIH-funded research R03 grant

Understanding how BRAF and RAF1 variants affect cell structure and signaling in a worm model

Official title: Investigation of RASopathy variants and Raf and Actin-Myosin regulation

Funded at University of Wisconsin Milwaukee · NIH-11354817 · Data updated 2026-11-12

This project studies how disease-linked changes in human BRAF and RAF1 genes alter Raf protein behavior and the cell’s skeleton using a worm model.

Quick facts

Grant typeR03 grant
Study typeNIH-funded research
Funding institutionUniversity of Wisconsin Milwaukee
NIH-funded
Lab location1 site (Milwaukee, United States)
Project startJune 1, 2026
Project endMay 31, 2028
Funding year2026
Award (this year)$144,064
NIH project number1R03HD121999-01
Project IDNIH-11354817 on NIH RePORTER

Who could benefit from this research

Could help

Patients with Noonan syndrome or Cardiofaciocutaneous syndrome caused by BRAF or RAF1 variants could benefit from future therapies informed by these results.

Less likely to help

Results may have limited immediate impact for individuals without these specific genetic variants or related conditions.

What this research studies

Researchers will use Caenorhabditis elegans strains with Raf variants that mirror human Noonan and Cardiofaciocutaneous syndromes to observe where Raf proteins go, how much is present, and how active they are inside living animals. They will also examine how hyperactive Raf affects Actin-Myosin networks and cytoskeleton organization, linking these cellular changes to potential drug targets. The goal is to identify cellular processes that could be blocked or modulated to treat RASopathy-related conditions. The work aims to inform future drug discovery by revealing distinct variant effects and shared disruptions in Raf signaling and cytoskeletal dynamics.

Why it matters

Potential benefit: If successful, findings could guide development of targeted therapies that modulate Raf signaling and cytoskeletal changes in children with RASopathy disorders.

How similar studies have gone: Prior work in C. elegans has shown that Raf variants can be studied in living animals with clear visualization of signaling and cytoskeletal changes, supporting this approach.

Where this research is happening

  • University of Wisconsin Milwaukee
    Milwaukee, United States
    Active

Researchers

  • Principal investigator: De la Cova, Claire — University of Wisconsin Milwaukee
  • Study coordinator: De la Cova, Claire

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.